Patient Information - General

A clinical trial, named OMICROHN, will be carried out to “clinically validate” a rapid blood test that will predict response to the biologic treatments adalimumab, vedolizumab and ustekinumab, the most frequently used medications for CD. The clinical trial will enroll 378 Crohn's Disease patients from the following 6 countries: Italy, Belgium, United Kingdom, Slovenia, Netherlands, and Hungary, via 54 well-established clinical sites.

During the study, similar data will also be collected from patients with rheumatoid arthritis or the skin disease psoriasis, so that this test can be developed for these patient groups in the future.

During the study, similar data will also be collected from patients with rheumatoid arthritis or the skin disease psoriasis, so that this test can be developed for these patient groups in the future.